Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 69

1.

[Propensity Score Comparison of the Various Radical Surgical Techniques for High-risk Prostate Cancer.]

Busch J, Gonzalgo M, Leva N, Ferrari M, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Magheli A.

Aktuelle Urol. 2014 Dec 19. [Epub ahead of print] German.

PMID:
25526221
[PubMed - as supplied by publisher]
2.

Matched comparison of robot-assisted, laparoscopic and open radical prostatectomy regarding pathologic and oncologic outcomes in obese patients.

Busch J, Gonzalgo ML, Leva N, Ferrari M, Cash H, Kempkensteffen C, Hinz S, Miller K, Magheli A.

World J Urol. 2014 May 23. [Epub ahead of print]

PMID:
24853030
[PubMed - as supplied by publisher]
3.

An Epigenetic Screen Unmasks Metallothioneins as Putative Contributors to Renal Cell Carcinogenesis.

Alkamal I, Ikromov O, Tölle A, Fuller TF, Magheli A, Miller K, Krause H, Kempkensteffen C.

Urol Int. 2014 Mar 20. [Epub ahead of print]

PMID:
24662736
[PubMed - as supplied by publisher]
4.

Optimizing evaluation of split renal function in a living kidney donor using scintigraphy and calculation of the geometric mean: a case report.

Weinberger S, Bäder M, Scheurig-Münkler C, Hinz S, Neymeyer J, Miller K, Kempkensteffen C.

Case Rep Nephrol Urol. 2014 Jan 10;4(1):1-4. doi: 10.1159/000358007. eCollection 2014 Jan.

PMID:
24575115
[PubMed]
Free PMC Article
5.

Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder.

Ebbing J, Mathia S, Seibert FS, Pagonas N, Bauer F, Erber B, Günzel K, Kilic E, Kempkensteffen C, Miller K, Bachmann A, Rosenberger C, Zidek W, Westhoff TH.

World J Urol. 2014 Dec;32(6):1485-92. doi: 10.1007/s00345-013-1227-8. Epub 2013 Dec 31.

PMID:
24378824
[PubMed - in process]
6.

Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.

Busch J, Magheli A, Leva N, Ferrari M, Kramer J, Klopf C, Kempkensteffen C, Miller K, Brooks JD, Gonzalgo ML.

BJU Int. 2014 Oct;114(4):517-21. doi: 10.1111/bju.12466. Epub 2014 Jan 22.

PMID:
24112652
[PubMed - indexed for MEDLINE]
7.

Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin.

Baumunk D, Reunkoff R, Kushner J, Baumunk A, Kempkensteffen C, Steiner U, Weikert S, Moser L, Schrader M, Höcht S, Wiegel T, Miller K, Schostak M.

BMC Med Inform Decis Mak. 2013 Aug 5;13:83. doi: 10.1186/1472-6947-13-83.

PMID:
23915212
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy.

Wotschofsky Z, Busch J, Jung M, Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller K, Kristiansen G, Erbersdobler A, Jung K.

Clin Chim Acta. 2013 Feb 1;416:5-10. doi: 10.1016/j.cca.2012.11.010. Epub 2012 Nov 21.

PMID:
23178446
[PubMed - indexed for MEDLINE]
9.

Long-term outcomes of living donor kidney transplants in pediatric recipients following laparoscopic vs. open donor nephrectomy.

Chaykovska L, Deger S, Roigas J, Lenz A, Lioudmer P, Kothmann LT, Friedersdorff F, Müller D, Kasper A, Giessing M, Magheli A, Kempkensteffen C, Lingnau A, Fuller TF.

Pediatr Transplant. 2012 Dec;16(8):894-900. doi: 10.1111/petr.12008.

PMID:
23131058
[PubMed - indexed for MEDLINE]
10.

Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.

Busch J, Seidel C, Erber B, Issever AS, Hinz S, Kempkensteffen C, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2013 Jul;64(1):62-70. doi: 10.1016/j.eururo.2012.09.004. Epub 2012 Sep 11.

PMID:
22999519
[PubMed - indexed for MEDLINE]
11.

Outcome of expanded criteria donor kidneys that were transplanted at other Eurotransplant centers after being rejected by our institution.

Friedersdorff F, Roller C, Klein G, Werthemann P, Cash H, Budde K, Slowinski T, Kempkensteffen C, Busch J, Fuller TF, Giessing M.

World J Urol. 2013 Aug;31(4):947-52. doi: 10.1007/s00345-012-0929-7. Epub 2012 Aug 18.

PMID:
22903774
[PubMed - indexed for MEDLINE]
12.

Outcomes after laparoscopic living donor nephrectomy: comparison of two laparoscopic surgeons with different levels of expertise.

Friedersdorff F, Werthemann P, Cash H, Kempkensteffen C, Magheli A, Hinz S, Waiser J, Liefeldt L, Miller K, Deger S, Fuller TF.

BJU Int. 2013 Jan;111(1):95-100. doi: 10.1111/j.1464-410X.2012.11348.x. Epub 2012 Jul 3.

PMID:
22757693
[PubMed - indexed for MEDLINE]
13.

Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience.

Busch J, Stephan C, Herold A, Erber B, Kempkensteffen C, Hinz S, Lein M, Weikert S, Miller K, Magheli A.

BJU Int. 2012 Dec;110(11 Pt C):E985-90. doi: 10.1111/j.1464-410X.2012.11279.x. Epub 2012 Jun 6.

PMID:
22672442
[PubMed - indexed for MEDLINE]
14.

Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis.

Busch J, Magheli A, Erber B, Friedersdorff F, Hoffmann I, Kempkensteffen C, Weikert S, Miller K, Schrader M, Hinz S.

BMC Urol. 2012 May 31;12:15. doi: 10.1186/1471-2490-12-15.

PMID:
22651395
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results.

Busch J, Stephan C, Klutzny A, Hinz S, Kempkensteffen C, Kilic E, Lein M, Weikert S, Miller K, Magheli A.

World J Urol. 2013 Apr;31(2):395-401. doi: 10.1007/s00345-012-0866-5. Epub 2012 May 11.

PMID:
22576695
[PubMed - indexed for MEDLINE]
16.

Selective lymph node dissection for castration-resistant prostate cancer.

Busch J, Hinz S, Kempkensteffen C, Erber B, Klopf C, Weikert S, Miller K, Magheli A.

Urol Int. 2012;88(4):441-6. doi: 10.1159/000335206. Epub 2012 Mar 7.

PMID:
22398510
[PubMed - indexed for MEDLINE]
17.

CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele.

Bolbrinker J, Seeberg S, Schostak M, Kempkensteffen C, Baelde H, de Heer E, Kreutz R.

Drug Metab Dispos. 2012 Apr;40(4):639-41. doi: 10.1124/dmd.111.042648. Epub 2012 Jan 3.

PMID:
22214815
[PubMed - indexed for MEDLINE]
Free Article
18.

Novel options for the treatment of castration-resistant prostate cancer.

Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ.

World J Urol. 2012 Aug;30(4):495-503. doi: 10.1007/s00345-011-0796-7. Epub 2011 Nov 20. Review.

PMID:
22101903
[PubMed - indexed for MEDLINE]
19.

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.

Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2011 Dec;60(6):1163-70. doi: 10.1016/j.eururo.2011.07.037. Epub 2011 Jul 21.

PMID:
21802830
[PubMed - indexed for MEDLINE]
20.

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.

Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V.

BMC Cancer. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295.

PMID:
21756335
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk